(Q45748092)

15 December 2017

title

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro (English)

1 reference

15 December 2017

1 reference

Gruber A

1

1 reference

15 December 2017

Speth C

2

1 reference

15 December 2017

Lukasser-Vogl E

3

1 reference

15 December 2017

Zangerle R

4

1 reference

15 December 2017

Borg-von Zepelin M

5

1 reference

15 December 2017

Dierich MP

6

1 reference

15 December 2017

Würzner R

7

1 reference

15 December 2017

publication date

1 April 1999

1 reference

15 December 2017

published in

Immunopharmacology

1 reference

15 December 2017

volume

41

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

227-234

1 reference

15 December 2017

Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

The SWISS-PROT protein sequence data bank and its supplement TrEMBL

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Putative virulence factors of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Role of aspartic proteases in disseminated Candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Stimuli that induce production of Candida albicans extracellular aspartyl proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Recovery of the immune system with antiretroviral therapy: the end of opportunism?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Oral candidiasis and human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Effect of HAART on natural history of AIDS-related opportunistic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

A specific inhibitor of keratinolytic proteinase from Candida albicans could inhibit the cell growth of C. albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2899%2900035-1

7 January 2021

10.1016/S0162-3109(99)00035-1

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017